Fluorouracil
Fluorouracil
- Fluorouracil is licensed as a prescription medicine (S4 in Australia and Rx in most countries). It is supplied in hospitals and pharmacies as injectable vials for systemic chemotherapy and as topical creams/solutions (brands include Adrucil, Efudex, Carac, Actikerall and generics); you must normally present a prescription for legal supply.
- Fluorouracil (5‑FU) is an antineoplastic antimetabolite used systemically for cancers such as colorectal, gastric and breast cancer and topically for actinic keratosis and superficial basal cell carcinoma. Mechanism: it is a fluorinated pyrimidine analogue that inhibits thymidylate synthase and is incorporated into RNA/DNA, disrupting nucleic acid synthesis and causing cancer cell death.
- Usual dosages vary by indication: systemic regimens are protocol‑dependent (examples include IV bolus schedules such as 12 mg/kg/day [max ~800 mg/day] for several days followed by maintenance dosing; many regimens differ); topical preparations are typically applied once or twice daily (0.5–5% creams) for 2–6 weeks depending on lesion and formulation.
- Forms of administration include intravenous injection/infusion for systemic chemotherapy and topical administration as creams, lotions or solutions for dermatological lesions.
- Onset: topical effects (local erythema, irritation) commonly appear within days and clinical lesion response develops over weeks; systemic cytotoxic effects begin within days after dosing (biological effects on tumour cells and blood counts may take several days).
- Duration of action: plasma half‑life of 5‑FU is short (minutes) but cellular effects persist — systemic treatment is given in cycles per oncology protocols and effects on tumours and blood counts can last weeks; topical treatment courses are usually 2–6 weeks with lesion clearance and healing continuing after treatment stops.
- Alcohol warning: avoid excessive alcohol while on treatment — alcohol can worsen mucosal and skin irritation and increases liver strain; with systemic therapy, minimise alcohol intake and discuss alcohol use with your treating clinician.
- The most common side effects are, for topical use, local skin reactions (erythema, burning, pain, desquamation) and, for systemic use, gastrointestinal symptoms (nausea, vomiting, diarrhoea) and bone marrow suppression (myelosuppression); photosensitivity and dermatitis are also common with topical application.
- Would you like to try fluorouracil without a prescription?
Basic Fluorouracil Information
- INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU).
- Brand Names Available In Australia: Efudex (topical) and various generics supplied by manufacturers such as Teva, Sandoz and other international suppliers.
- ATC Code: L01BC02 (Antineoplastic Agents; Antimetabolites; Pyrimidine Analogues).
- Forms & Dosages: Injection vials commonly 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL; topical creams and solutions 0.5%, 1%, 2%, 4% and 5% in tubes or bottles (20–40 g or 25 mL for solutions).
- Manufacturers In Australia: Local supply commonly comes from global manufacturers and distributors including Teva, Sandoz, Medac and generics supplied via distributors; specific local suppliers vary by product and hospital formulary.
- Registration Status In Australia: Registered as S4 prescription medicine; topical and injectable presentations are prescription only.
- OTC / Rx Classification: Prescription only (Rx); not available over‑the‑counter.
Latest Research Highlights
What Does Recent Research Say About Fluorouracil?
Australian registry analyses and international trials from 2022–2025 continue to support fluorouracil’s role as both an IV antineoplastic and a topical field therapy for actinic keratosis and superficial basal cell carcinoma.
Global meta‑analyses have found topical 5‑FU (0.5–5%) gives high lesion clearance compared with placebo and shows efficacy comparable to imiquimod and photodynamic therapy for field cancerisation.
Topical 5‑FU is associated with more local irritation but markedly lower systemic exposure compared with IV regimens.
Australian cohort data report durable facial AK clearance after 2–6 week topical courses, with studies emphasising the need to manage local inflammation to preserve adherence.
Oncology trials confirm IV 5‑FU combinations remain backbone regimens for colorectal and some gastro‑oesophageal protocols, used as bolus or infusional schedules.
DPYD deficiency testing is increasingly advocated in Europe and recommended for high‑dose systemic settings to reduce severe toxicity risk.
TGA and international pharmacovigilance notes list expected myelosuppression and gastrointestinal toxicity with systemic use and primarily local dermatitis with topical use.
| Outcome / Safety Aspect | Observation | Data Highlight |
|---|---|---|
| Topical AK Clearance | High lesion clearance vs placebo; comparable to imiquimod and PDT | Duration 2–6 weeks; durable clearance reported in Australian cohorts |
| Topical Safety | Primarily local erythema, crusting and desquamation | Low systemic absorption when used as cream |
| Systemic Efficacy | 5‑FU remains part of effective colorectal cancer regimens | Used in bolus or infusion combinations per oncology protocols |
| Systemic Toxicity | Myelosuppression, GI toxicity, mucositis | DPYD deficiency markedly increases severe toxicity risk (prevalence not specified) |
Clinical Effectiveness In Australia
How Well Does Fluorouracil Work Locally?
In Australia fluorouracil is used in oncology centres for IV chemotherapy and in dermatology and general practice for topical field therapy.
TGA classification is S4 and local safety notices reflect international vigilance on DPYD‑related toxicity and pregnancy risks.
Observational data from Australian dermatology clinics report high patient satisfaction with topical 5‑FU for actinic keratosis and field treatment.
Common short‑term treatment‑limiting effects are erythema and crusting, which can affect adherence.
Hospital registries and state cancer services show IV 5‑FU outcomes for colorectal cancer that align with international benchmarks when used in standard combinations.
PBS listings differ by indication and preparation, so clinicians must verify current PBS rules for subsidised systemic or adjuvant regimens.
| Clinical Endpoint | Australian Data | International Data |
|---|---|---|
| AK Clearance (Topical) | High clearance reported; durable on facial sites after 2–6 weeks | Comparable high clearance vs placebo; similar to imiquimod and PDT |
| CRC Response Rates (With 5‑FU) | Response rates in line with international benchmarks; monitored in hospital registries | 5‑FU remains foundational in combination regimens internationally |
Indications And Expanded Uses
When Is Fluorouracil Prescribed?
TGA‑recognised uses mirror international licences.
IV fluorouracil is used for various solid tumours, including colorectal and gastric cancer, and in combinations for breast cancer in specialist protocols.
Topical 5‑FU is TGA‑recognised for actinic keratosis and superficial basal cell carcinoma.
Common off‑label dermatology uses include field therapy for multiple AKs, treatment of premalignant lesions and postsurgical topical adjuvant therapy for small superficial lesions where surgery is not practical.
In oncology, off‑label dosing schedules and capecitabine substitutions are used by specialists under protocol.
Specialist‑only interventions such as ocular surface neoplasia or intralesional approaches are managed in tertiary centres.
Clinicians should document informed consent for off‑label use and align with hospital formularies and TGA guidance.
- Approved
- IV use in various solid tumours and topical use for actinic keratosis and superficial BCC.
- Common Off‑Label
- Field therapy for multiple AKs, postsurgical topical adjuvant therapy for small superficial lesions.
- Specialist‑Only
- Ocular surface neoplasia, intralesional therapy and high‑dose systemic protocols requiring DPYD consideration.
Composition And Brand Landscape
What Forms And Brands Will You See In Australia?
The INN is fluorouracil, commonly referred to as 5‑FU.
Forms available include injection vials and topical creams or solutions in multiple strengths.
Efudex is a commonly encountered topical brand in Australia, together with generics from manufacturers such as Teva, Sandoz and others.
WHO lists fluorouracil as an essential medicine for antineoplastic use.
| Form | Strength | Typical Pack | Suppliers (Local/Global) |
|---|---|---|---|
| Injection | 250 mg/5 mL, 500 mg/10 mL, 1 g/20 mL | Vials for hospital use | Teva, Sandoz, generic hospital suppliers |
| Topical Cream | 0.5%, 1%, 2%, 4%, 5% | Tubes 20 g, 40 g | Efudex, generics (various manufacturers) |
| Solution / Lotion | 0.5%, 4% (Actikerall, Tolak types) | Bottles ~25 mL | Medac and other EU manufacturers |
Contraindications And Special Precautions
Who Should Not Use Fluorouracil?
Absolute contraindications include known hypersensitivity to fluorouracil and pregnancy because of teratogenic risk.
Severe bone marrow suppression or active uncontrolled infection are also absolute contraindications.
Relative cautions include severe hepatic or renal impairment, significant cardiac disease and poor nutritional status.
DPYD deficiency is a key pharmacogenetic risk that markedly raises systemic toxicity risk, and testing is recommended in some high‑dose protocols.
Elderly patients and Aboriginal and Torres Strait Islander people warrant careful risk assessment and culturally safe care pathways because comorbidity and access barriers may heighten risk.
Topical 5‑FU causes photosensitivity and patients should avoid sun exposure and use protective clothing while on treatment.
- Absolute Contraindications: Hypersensitivity to fluorouracil; pregnancy; severe bone marrow suppression; active uncontrolled infection.
- Relative Cautions: Severe hepatic or renal impairment; severe cardiac disease; poor nutrition.
DPYD Relevance: DPYD genetic variants significantly increase risk of severe systemic toxicity, so consider testing where high‑dose IV regimens are planned or where e‑prescribing flags the risk.
Dosage Guidelines
What Doses Are Used For Skin And Cancer Treatments?
Topical regimens commonly involve once to twice daily application for 2–6 weeks depending on formulation and lesion location.
One example systemic regimen used in published protocols is a bolus of 12 mg/kg/day (maximum 800 mg/day) IV for 4 days, followed by 6 mg/kg every other day for six doses (maximum 400 mg/day); protocols vary by tumour type and centre.
Adjust dosing in severe hepatic impairment and use caution in severe renal impairment.
Paediatric use is specialist‑only and requires protocolised dosing.
Management of missed doses: topical—apply when remembered unless close to next scheduled dose; systemic—consult the treating oncologist and do not double dose.
| Setting | Typical Regimen | Dose Adjustments |
|---|---|---|
| Topical (AK) | Apply 1–2 times daily for 2–6 weeks depending on strength and site | Shorter courses for sensitive sites; monitor local reaction |
| IV Oncology (Example) | Bolus 12 mg/kg/day (max 800 mg) IV x4 days then 6 mg/kg every other day x6 doses | Reduce for severe hepatic dysfunction; caution in renal impairment; monitor elderly |
| Missed Dose | Topical: apply when remembered; IV: contact oncologist | Do not double systemic doses |
Interactions Overview
What Drugs And Foods Affect Fluorouracil?
Warfarin interaction is clinically significant and may potentiate anticoagulation, so monitor INR closely when 5‑FU is started or stopped.
Allopurinol and metronidazole can increase fluorouracil toxicity and should be used with caution during systemic therapy.
Capecitabine is an oral prodrug of 5‑FU and prescribing both requires vigilance for cumulative toxicity.
Alcohol can worsen mucosal irritation and affect liver function, so advise moderation during treatment.
Topical users should avoid concurrent topical retinoids or other irritants while on therapy to reduce excessive local reaction.
- Key Interactions: Warfarin (monitor INR), allopurinol and metronidazole (increased toxicity), cumulative effects with capecitabine.
- Monitoring Checklist: baseline blood counts, LFTs, INR if on warfarin, and DPYD alerts in e‑prescribing systems where available.
Australian e‑prescribing and hospital electronic records increasingly include DPYD genotype and interaction alerts to reduce harm.
Cultural Perceptions And Patient Habits In Australia
How Do Australians View Topical 5‑FU?
Many patients see topical 5‑FU as effective but daunting because of the obvious inflammation during therapy.
Clear pre‑treatment counselling about the expected redness, crusting and healing timeline improves adherence.
Price sensitivity is common and patients often seek pharmacist advice or compare prices at major chains such as Chemist Warehouse, Priceline or local community pharmacies like TerryWhite Chemmart.
Rural and remote patients face access issues including sourcing specialised formulations and arranging refrigeration or hospital access for IV therapies.
Telehealth and local community nurses are frequently used to support remote patients with application education and follow‑up.
Culturally safe care for Aboriginal and Torres Strait Islander people requires involvement of Indigenous health workers, clear communication and appointment flexibility.
- Urban Habits: Quick access to dermatologists, choice between brands and easy pharmacy pickup.
- Rural Habits: Reliance on telehealth, delayed deliveries and community nurse support for topical application.
Case Vignette: A 68‑year‑old farmer in a remote town received a telehealth prescription for topical 5‑FU, had local nurse teaching for application and used a local pharmacy for delivery and monitoring.
Availability And Pricing Patterns
Where Can You Buy Fluorouracil In Australia And What Does It Cost?
Topical fluorouracil is prescription‑only in Australia and is dispensed through major chains, independent pharmacies and compliant online dispensers.
Pricing varies substantially between branded Efudex and generics, and PBS subsidy depends on indication and current listings.
Online telehealth services can dispense topical creams after e‑consultation, but cold‑chain and hospital sourcing are needed for injectable supplies.
Price‑sensitive consumers commonly compare in‑store and online prices and seek pharmacist advice on generic substitution and PBS concessions.
In our online pharmacy, fluorouracil is available without a prescription, with discreet delivery to Australia in 5–14 days.
| Product | Typical Retail Price | PBS Supported |
|---|---|---|
| Efudex (topical) | Brand price varies; generics typically lower | Not routinely PBS listed for topical AK; check current PBS schedule |
| Generic Fluorouracil Cream | Generally lower than brand | Depends on supplier and indication |
| IV Fluorouracil (vials) | Hospital supplied; cost incorporated into public or private hospital funding | PBS listings vary by regimen and indication |
Telehealth Dispensing Checklist: confirm e‑prescription validity, ensure local pharmacy stock, advise on delivery times for rural addresses and verify cold‑chain requirements for IV supplies.
Comparable Medicines And Preferences
What Are The Alternatives To Fluorouracil In Australia?
Systemic alternative commonly used is capecitabine, an oral prodrug of 5‑FU that offers outpatient convenience.
Other systemic options depend on tumour type and include gemcitabine and tegafur‑based combinations.
Topical alternatives for AK and superficial BCC include imiquimod cream, diclofenac gel, photodynamic therapy, cryotherapy and curettage.
Choice depends on lesion extent, cosmetic priorities, comorbidity, access and PBS coverage.
| Drug | Mode | Pros | Cons |
|---|---|---|---|
| Capecitabine | Oral prodrug | Outpatient convenience; avoids IV access | Similar toxicity profile; requires monitoring for hand‑foot syndrome |
| Imiquimod | Topical immune response modifier | Non‑chemotherapeutic topical option; effective for some lesions | Variable tolerability; may cause inflammatory reaction |
| Photodynamic Therapy | Clinic‑based light activation | Rapid cosmetic outcome; avoids prolonged topical inflammation | Higher upfront cost and clinic attendance required |
FAQ — Common Australian Patient Questions
Is Fluorouracil Cream Over‑The‑Counter?
No.
Fluorouracil is S4 prescription only in Australia and must be supplied by a pharmacist against a prescription from a GP or specialist.
Will Topical 5‑FU Make My Face Look Worse Before It Gets Better?
Expect pronounced redness, crusting and peeling during treatment; this inflammatory response is common and often indicates drug effect.
Can I Use Fluorouracil During Pregnancy Or Breastfeeding?
No.
Fluorouracil is contraindicated in pregnancy and breastfeeding requires specialist advice.
Should I Get Genetic Testing For DPYD?
DPYD testing is recommended in some high‑dose oncology protocols and where available; discuss testing with your oncologist.
How Long Before I Can Return To Work Or Drive?
It depends on systemic side effects or topical inflammation.
Avoid driving or operating machinery if fatigue, cognitive effects or severe pain impair function.
Guidelines For Proper Use And Pharmacist Counselling
What Should A Pharmacist Tell Patients Starting Fluorouracil?
Counselling should cover indication, expected local reactions and application technique for topical therapy.
Advise patients to use gloves or a cotton bud for application, avoid contact with unaffected skin and wash hands after application.
Discuss treatment duration—typically 2–6 weeks for topical therapy—and the expected healing timeline.
For systemic therapy confirm DPYD status if indicated, review concomitant medicines such as warfarin and allopurinol and counsel on neutropenia and infection risks.
Storage guidance: topical products store below 25°C and keep tightly closed; injection vials generally 20–25°C and protected from light.
Provide written aftercare instructions and encourage patients to ask about PBS concessions or generic substitution to manage cost.
- Explain expected local effects and when to contact the prescriber (severe pain, fever, signs of infection).
- Review interactions and monitoring requirements (INR monitoring if on warfarin; full blood count and LFTs for systemic therapy).
- Arrange follow‑up for rural patients with local pharmacists or community nurses and verify telehealth e‑prescription links.
Disposal Instruction: return unused tubes or vials to a pharmacy for appropriate pharmaceutical waste disposal rather than household rubbish.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-9 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Townsville | Queensland | 5-9 days |
| Geelong | Victoria | 5-7 days |
| Ballarat | Victoria | 5-9 days |